Generated by Meeveem AI
"Global biopharmaceutical company transforming lives through precision medicines for rare diseases"
Rhythm Pharmaceuticals develops precision medicines for patients living with rare neuroendocrine diseases. The company's lead asset, IMCIVREE, targets severe obesity caused by impairments in the melanocortin-4 receptor pathway in the hypothalamus. Rhythm addresses diseases that were previously untreatable, providing meaningful support for healthcare providers, patients, and their families. The company advances a full portfolio of treatment options for patients with hyperphagia and obesity, ensuring they receive the right treatment. With more than 400 employees across North America and Europe, Rhythm combines scientific rigour with patient-focused innovation, pioneering a path forward for families affected by rare genetic conditions.
414
Team Members
2008
Founded
Pharma
Sector
On-Site
Work Environment
Patients with rare neuroendocrine diseases live their fullest lives, transformed through optimal, stigma-free care.
To transform the lives of patients with rare neuroendocrine diseases by rapidly advancing care and precision medicines that address the root cause.